Evidence map›Paper›PMID 40496869›Full record

ArticleFrontiers in immunology2025

CyTOF reveals platelet subtype changes predicting the efficacy of combined immunotherapy and targeted therapy in liver cancer.

Wenjing Wang, Dan Liu, Lilin Wang, Maimaitijiang Wubuli Aishan, Li Chen, Sujun Zheng, Junfeng Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenjing Wang *Beijing Institute of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Dan Liu *First Department of Liver Disease, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Lilin WangFirst Department of Liver Disease, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Maimaitijiang Wubuli AishanDepartment of Liver Disease, Hotan District Infectious Disease Specialist Hospital, Hotan, Xinjiang Autonomous Region, China.
Li ChenDepartment of Liver Disease, Hotan District Infectious Disease Specialist Hospital, Hotan, Xinjiang Autonomous Region, China.
Sujun ZhengFirst Department of Liver Disease, Beijing YouAn Hospital, Capital Medical University, Beijing, China.
Junfeng LuFirst Department of Liver Disease, Beijing YouAn Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Immune checkpoint inhibitors combined with angiogenesis inhibitors are currently the first-line treatment for liver cancer. However, some patients still exhibit poor therapeutic outcomes. Platelets, as a critical component of blood, play a significant role in liver cancer progression by influencing angiogenesis and the tumor immune microenvironment. Methods: In our study, we utilized mass cytometry (CyTOF) to analyze surface proteins on platelets in the plasma of 23 liver cancer patients before and after receiving combined immunotherapy and targeted therapy. Patients were grouped based on treatment efficacy to compare platelet subpopulation differences. Results: We observed that CD107a+ and CD62P+ platelet subpopulations were reduced in liver cancer patients. In the progressive disease (PD) group, the CD29+ platelet subpopulation was elevated compared to other groups. Notably, this subpopulation decreased with tumor remission and increased with tumor progression. Discussion: Our findings highlight the heterogeneity of platelets in liver cancer patients and suggest that the CD29+ platelet subpopulation may serve as a predictive biomarker for the efficacy of combined immunotherapy and targeted therapy. Additionally, CD29+ platelets could represent a potential therapeutic target in future research.

Indexed as

Blood PlateletsImmunotherapyLiver NeoplasmsAgedBiomarkers, TumorFemaleFlow CytometryHumansImmune Checkpoint InhibitorsMaleMiddle AgedMolecular Targeted TherapyTreatment OutcomeTumor MicroenvironmentBiomarkers, TumorImmune Checkpoint InhibitorsCD29+combined immunotherapy and targeted therapyCyTOFliver cancerplatelets

Identifiers

PMID40496869
PMCPMC12149196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.